In light of the relatively disappointing single agent activity of rapalogs in prostate cancer, it may be critical to assess the MYC status of prostate tumors (among several other markers) to guide the interpretation of response data in patients undergoing PI3K inhibitor therapy. Here, MYC is linked to prostate neoplasm.